KIT and ovarian serous adenocarcinoma: Human serous ovarian cancer patient-derived xenografts (PDXs) showed that CD117+ cells isolated from the xenografts were able to recapitulate a tumor with only 10,000 cells; this was a 100-fold increase in tumor initiating capability compared with the CD117− cells [68].